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The Lmo2 transcription factor, a T-cell oncoprotein, is required for both hematopoiesis and angiogenesis. To investigate the fate of
lmo2-expressing cells and the transcriptional regulation of lmo2 in vivo, we generated stable transgenic zebrafish that express green
fluorescent protein (EGFP) or DsRed under the control of an lmo2 promoter. A 2.5-kb fragment contains the cis-regulatory elements
required to recapitulate endogenous lmo2 expression in embryonic hematopoietic and vascular tissues. We further characterized embryonic
Lmo2+ cells through transplantation into vlad tepes (vlt), an erythropoietic mutant. These Lmo2+ primitive wave donor cells differentiated
into circulating hematopoietic cells and extended the life span of vlt recipients, but did not demonstrate long-term repopulation of the
erythroid lineage. Promoter analysis identified a 174-bp proximal promoter that was sufficient to recapitulate lmo2 expression. This
element contains critical ETS-binding sites conserved between zebrafish and pufferfish. Furthermore, we show that ets1 is coexpressed
with lmo2, and overexpression experiments indicate that ets1 can activate the lmo2 promoter through this element. Our studies elucidate
the transcriptional regulation of this key transcription factor, and provide a transgenic system for the functional analysis of blood and
blood vessels in zebrafish.
D 2005 Elsevier Inc. All rights reserved.
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Hematopoietic stem cells (HSCs) and vascular progen-
itors are derived from ventral mesoderm during vertebrate
ontogeny (Zon, 1995). In zebrafish, bilateral mesodermal
stripes begin to express the hematopoietic markers lmo2,
scl/tal1, and gata2 shortly after gastrulation (Thompson
et al., 1998). These mesodermal cells are specified to0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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converge towards the midline to form the Intermediate
Cell Mass (ICM), a tube-like structure of endothelial cells
encasing primitive erythrocytes. Observations in other
model systems have shown that a second wave of HSCs
in the Aorta–Gonad–Mesonephros cell clusters within the
ventral wall of the dorsal aorta can generate all
hematopoietic lineages over the life span of transplanted
adult animals (Muller et al., 1994). Experiments in
several animal models have shown that hematopoietic
and endothelial stem cells develop in close association
spatially and temporally, as well as express a common set
of marker genes (Robertson et al., 1999). Therefore, it281 (2005) 256–269
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a common progenitor cell called the hemangioblast (Choi
et al., 1998; Sabin, 2002; Shalaby et al., 1995; Stainier
et al., 1995).
The genetic pathways governing the specification of
putative hemangioblasts remain elusive. Two transcription
factors, encoded by the stem cell leukemia (Scl/Tal-1) and
lim-only Lmo2 genes, are necessary for primitive hema-
topoiesis and normal endothelial development in verte-
brates, lending support to the hypothesis that these genes
mark the hemangioblast (Warren et al., 1994; Yamada et
al., 1998). Lmo2 was first identified as an oncogene via
chromosomal translocation in T-cell acute lymphoblastic
leukemia (T-ALL) (Royer-Pokora et al., 1995). Recently,
retroviral integration into the Lmo2 promoter region was
determined to be the cause of T-ALL identified in two
gene therapy patients undergoing treatment for X-linked
severe combined immunodeficiency (Hacein-Bey-Abina et
al., 2003). Lmo2 expression has also been shown to be the
strongest genetic predictor of increased survival in diffuse
large-B-cell lymphoma (Lossos et al., 2004). Normally,
Lmo2 is expressed in blood and endothelial progenitors, a
pattern that is conserved across vertebrate species from
teleost fish to mammals. Mice lacking Lmo2 are severely
anemic and die at E9–10 due to a failure in yolk sac
erythropoiesis (Warren et al., 1994). In mouse chimeras,
Lmo2/ ES cells do not contribute to any adult blood
lineages, demonstrating its requirement in definitive
hematopoiesis. In these chimeric animals, Lmo2/ cells
integrate into the nascent vascular network, but as
development progresses, the vessels become highly dis-
organized (Yamada et al., 1998), suggesting that LMO2 is
required for angiogenesis but is dispensable for vasculo-
genesis. Furthermore, forced expression of lmo2 and scl/
tal-1 during Xenopus and zebrafish development results in
the excess formation of blood and endothelial cells,
demonstrating that these genes are capable of specifying
these tissues within mesoderm (Gering et al., 1998, 2003;
Mead et al., 2001).
It remains unclear how Lmo2 and Scl/Tal-1 expression
are initiated and maintained during development. While
much attention has been given to the transcriptional
regulation of Scl/Tal-1, less is known about the regulation
of Lmo2. The human Lmo2 locus contains two promoters: a
proximal promoter that functions in multiple tissue types
and a distal promoter that is restricted to hematopoietic
lineages (Royer-Pokora et al., 1995). In addition, a 180-bp
regulatory element that has activity in erythroid cell lines
was found to contain functional PAR and E-box motifs
(Crable and Anderson, 2003). Until now, no in vivo
transcriptional analysis of lmo2 expression has been
reported.
Because the genetic program for hematopoiesis and
vasculogenesis is conserved in zebrafish, we exploited
transgenic technology to investigate the transcriptional
regulation of lmo2 in zebrafish in an effort to elucidatemechanisms by which these tissues are patterned in all
vertebrates. We established transgenic zebrafish expressing
EGFP and DsRed under the control of a 2.5-kb lmo2
promoter, which was sufficient to drive blood and
vascular expression. Transplantation of Lmo2+ cells
harvested from these transgenic embryos during primitive
hematopoiesis demonstrated that these cells could give
rise to blood and blood vessel cells in recipients.
Identification of a critical cis-element containing func-
tional ETS-domain transcription factor binding sites (EBS)
implicate ETS factors as regulators of lmo2 during early
hematopoietic and vascular development. Our studies
establish a framework for understanding the transcriptional
regulation of this important gene.Materials and methods
Zebrafish strains and maintenance
Fish and embryos were maintained, collected, and
staged as described (Westerfield, 1993). clochem39 (Stain-
ier et al., 1995), moonshine (Ransom et al., 1996), and
mindbombta52b (provided by Bruce Appel) heterozygote in-
dividuals were outcrossed to heterozygote Tg(lmo2:EGFP)
(LGb) individuals and offspring were incrossed to yield
homozygous mutants in the transgenic background.
Generation of constructs and transgenic lines
A zebrafish genomic PAC library was screened with a
32P-radio-labeled probe containing a region of zebrafish
lmo2 cDNA that encodes a conserved LIM domain. A
positive PAC clone was identified and digested with EcoRI
and subcloned into pBluescript II KS(+). Constructs II and
III were generated by ligating a 2.5-kb fragment amplified
by PCR into the pEGFP-1 or pDsRed2-1 vectors
(Clontech). The promoter contains 5V flanking sequences
upstream of the lmo2 transcriptional start site. A detailed
description of the cloning of this construct is available
upon request. The promoter-EGFP was liberated by
digesting with EcoRI and NaeI, purified following electro-
phoresis using Qiaquick Gel Purification Kit, and resus-
pended in 10–15 Al of nuclease-free water. Constructs
were injected at 100 ng/Al of DNA, 0.2 M KCl into one-
cell-staged wild-type AB embryos no later than 30 min
following fertilization using standard protocols (Xu, 1999).
Pairs of sibling adults grown from injected embryos were
incrossed to identify germline founders.
In situ hybridization
Whole mount in situ hybridization was performed as
described previously (Westerfield, 1993). Antisense digox-
igenin and fluorescein-labeled RNA probes were generated
from cDNA clones using an RNA labeling kit.
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Embryos were dechorionated using pronase and held in
E3 for imaging. At later time points, embryos were
anesthetized by placing in E3 and tricaine methanesulfonate
(Sigma, St. Louis, MO). Embryos were visualized with an
inverted fluorescent microscope (Leica DM-IRE2). Imaging
was performed using a Hammamatsu Orca-ER digital
camera and Openlab software.
Embryonic cell collection, flow cytometry, and hemato-
poietic cell transplantation
Embryos were dechorionated with pronase and disrupted
in ice-cold 0.9% PBS containing 5% FCS using a pellet
pestle. Cells were passed through a 40-Am nylon mesh filter,
washed twice and collected by centrifugation at 400 g for 5
min. Cells were resuspended in 0.9% PBS, 5% FCS and
propidium iodide (PI, Sigma) was added at 1 Ag/ml to exclude
dead cells and debris. FACS analysis and sorting was
performed based on PI exclusion, forward scatter, side
scatter, GFP, and/or DsRed fluorescence using a FACS
Vantage flow cytometer (Beckton Dickinson). Approxi-
mately 5  105 EGFP+ cells were sorted. Transplantations
were performed as described in Traver et al. (2003).
Promoter analysis
Deletion constructs for promoter analysis were made




LG147 was isolated by digesting plmo2-EGFP with AflII.
The reverse primer used in all cases was made against the 3V
end of pEGFP-1. Mutant promoters were made with
QuickChangeR site-directed mutagenesis kit (Stratagene).
Forward primers used for LG2.5e1-, e2- and e3- are listed in
Fig. 7A. Forward primer for used to generate LG2.5e2,3-: 5V-
GCCGTCGTGAGCAAGCGGTCTCTAAAGAGCA-
GAAACTGAG-3V. The sequences of LG2.5D170/67 and
LG2.5D170/+41 are provided in the supplemental materi-
als, and subcloning details can be provided upon request.
Microinjection
ets1 cDNA was subcloned into pCS2+ for mRNA
synthesis. mRNA was injected between the 1- and 4-cell
stages at a concentration of 300 ng/Al. A morpholino of ets1
(ets1-spliceMO: GATGACTTACGTCTACTTTTTCGGA)
that disrupts splicing at the 1st exon–intron junction was
obtained from Gene Tools LLC and solubilized in 1
Danieau solution. Embryos were injected with 1 nl ets1-
spliceMO at a concentration of 7 ng/Al.Electrophoretic mobility shift assay
ets1 and ets1DN proteins were made from the TNTR
Quick Coupled Transcription/Translation System Kit from
Promega. EMSA was performed as described previously
(Bockamp et al., 1998). Oligonucleotides are shown in Fig. 7.Results
The lmo2 promoter drives expression that mirrors
endogenous lmo2
In an effort to examine the regulation of the zebrafish lmo2
gene, a 2.5-kb lmo2 promoter fragment was subcloned up-
stream of the EGFP and DsRed fluorescent reporter genes
(Fig. 1a). Stable transgenic lines using these constructs were
made by standard methods (Meng et al., 1999). Of 50 adult
animals screened, five independent Tg(lmo2:EGFP) lines
(designated LGa through LGe) were identified, while only
one Tg(lmo2:DsRed) founder (designated LR) was isolated
from 65 animals screened. LGa, LGb, and LR showed
embryonic expression similar to endogenous lmo2 and were
thus bred for further investigation. Unless otherwise noted,
LGb was the Tg(lmo2:EGFP) line used for subsequent
experiments.
To determine if the 2.5-kb promoter recapitulated the
endogenous lmo2 expression pattern, we compared EGFP
mRNA and protein localization to the lmo2 whole mount
in situ hybridization pattern. lmo2 and EGFP transcripts
first appeared in two stripes of posterior lateral mesoderm
at the 1-somite stage, and expression continued in these
cells at 5 somites (Fig. 1b, A–D). Simultaneously, anterior
vascular precursors also expressed EGFP (Fig. 1b, E,F).
Because the EGFP protein requires several hours to
mature, fluorescence was not detected until approximately
8 somites. Between the 8- and 18-somite stages, con-
vergence of the lmo2, EGFP+ bilateral mesodermal cells
could be visualized (Fig. 1b, G,H). In LGb, sprouting of
the intersomitic vessels from the ICM was detected at 24
hpf (Fig. 1b, J). From 24 to 36 hpf, the circulating blood
and most vessels including the cardinal vein and aorta
were fluorescent. At 36 hpf, endogenous lmo2 expression
marked the presumptive AGM region in the ventral aspect
of the aorta (Fig. 1b, M). EGFP was observed in the trunk
vasculature including the cells in this region (L, inset),
although it was not clear if the transgene is expressed in
the putative AGM stem cell clusters. In LGb, EGFP levels
began to fall at 24 hpf and become nearly undetectable by
48 hpf, a pattern that mirrors endogenous lmo2 expression.
Weak expression in adult erythrocytes and endothelial cells
was seen in LGa and LR but not LGb (data not shown).
We conclude that the 2.5-kb lmo2 promoter contains the
cis-regulatory elements necessary to recapitulate endoge-
nous lmo2 expression in hematopoietic and endothelial
cells during embryogenesis.
Fig. 1. EGFP expression under the control of a 2.5-kb lmo2 promoter recapitulates endogenous lmo2 expression. (a) Constructs used to generate the lmo2
transgenic lines are shown. Construct I is a 5-kb genomic fragment derived from a PAC clone that contains exons 1 and 2 of lmo2. Constructs II and III are 2.5 kb of
the 5-kb fragment ligated to the reporter genes EGFP-1 and DsRed2-1. (b) EGFP and lmo2 transcripts first appear in two lateral stripes of ventral mesoderm (black
arrowheads) by the 1-somite stage as shown in A and B. Transcripts can been detected at the 5-somite stage (C, D). Anterior vascular precursors express EGFP and
lmo2 at 5 somites (E, F). At 12 somites, the posterior mesoderm stripes migrate to form the ICM (G). By the 18-somite stage, most of the ICM has formed from the
convergentmorphogenesis of the stripes (H, I). At 24 hpf, circulating blood (white arrow) andmost of the vasculature, including the cardinal vein, dorsal aorta, and
branching intersomitic vessels (white arrowhead), are fluorescent (J), which replicate that of endogenous lmo2 expression in K. In line LGb, EGFP is
downregulated over the next 24 h, but vascular expression persists (L); the aorta and vein are fluorescently labeled during the formation of the presumptiveAGMat
36 hpf (inset and white arrow). Endogenous lmo2 is expressed at low levels in the trunk vessels at 36 hpf (black arrow) (M).
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hematopoietic and vascular systems
The expression pattern of LR was nearly identical to that of
the EGFP lines, with two exceptions. The DsRed protein
requires approximately 12 h to mature and is much more
stable than EGFP, so DsRed was first detected at 20 hpf (Fig.2A) and protein levels were maintained for a longer period of
time (Fig. 2B is a confocal image showing cranial vessel
expression at 3 dpf). See Supplemental Movie 1 in Appendix
A to see the circulation of a 2 dpf LR embryo.
To further characterize LR and to distinguish hemato-
poietic from vascular cell populations in living embryos, we
mated LR to Tg(fli1:EGFP), a line that strictly labels
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Tg(gata1:EGFP), a line that strictly labels erythrocytes
(Long et al., 1997). In LR; Tg(fli1:EGFP) embryos, the vas-
culature was labeled with EGFP through adulthood, and the
vasculature and blood were labeled with DsRed for more than
1 month (Figs. 2D,E). Fig. 2C is a confocal micrograph of
fluorescent red erythrocytes circulating through green cranial
vessels in 3 dpf embryos. Since erythroid progenitors and
their progeny coexpress lmo2 and gata1, these cells
expressed DsRed and EGFP in LR; Tg(gata1:EGFP), the
second double transgenic line we generated (Figs. 2F,G). In
these embryos, angioblasts and endothelial cells were
DsRed+/EGFP, and thus could be distinguished from
yellow erythroid cells expressing both proteins. Examining
this DsRed line in the background of other GFP-expressing
hematopoietic and vascular transgenics demonstrates that
these tissues can be distinguished by fluorescent gene ex-
pression even if they cannot be distinguished by morphology.
The transgenic lines also facilitated visualization of living
embryos with defective hematopoietic and vascular develop-
ment (Figs. 2H–J). Three recessive mutant strains were
crossed to LGb and the offspring were incrossed to generate
homozygous embryos carrying the EGFP transgene. In the
zebrafish clocheM39 (clo) mutant, there is no formation of
hematopoietic cells and severely disrupted vasculogenesisFig. 2. The lmo2 transgenic lines facilitate visualization of hematopoietic and vasc
protein is initially detected at 20 hpf (inset); 2 dpf LR embryos labeling hematopo
The cranial vessels of a 3 dpf LR embryo visualized by confocal microscopy (BA,
Confocal section through the head and trunk of a 3 dpf LR; Tg(fli1:EGFP) em
(arrowhead, E). (D,E) LR; Tg(fli1:EGFP) embryos distinctly label hematopoietic
LR; Tg(gata1:EGFP) transgenic embryos, green/red erythrocytes (arrowheads) ci
3 dpf embryos (F and G, respectively). In the second panel, 24–36 hpf mutant
mutant, there is an absence of hematopoietic cells and virtually no endothelium
expression is known to be preserved. (I) In moonshine, normal vasculature is
malformations (arrow points to fusion between artery and vein) are identified w(Stainier et al., 1995). lmo2 expression is restricted to the
posterior ICM region in clo embryos, a pattern that was
recapitulated in 24 hpf clo/; LGb embryos (Fig. 2H).
moonshine (mon) mutants exhibit normal vasculogenesis, but
lack erythroid development (Ransom et al., 1996). Therefore,
no circulating cellswere seen inmon/ embryos carrying the
LGb transgene (Fig. 2I). mindbomb (mib) encodes an E3
ubiquitin ligase required for Notch signaling, and mib/
embryos exhibit defects in vascular development (Appel et
al., 1999; Jiang et al., 1996; Itoh et al., 2003; Schier et al.,
1996). Fig. 2J shows a mib/; LGb embryo in which blood
cells traveled through regions where artery and vein were
fused. These transgenics allowed us to observe two cell types
in wild-type and mutant backgrounds, which will prove
invaluable for the tracking of subpopulations in fate mapping
and transplantation experiments.
Primitive hematopoietic progenitors differentiate into
erythrocytes and can partially rescue the vlad tepes mutant
To determine the extent to which primitive wave pro-
genitors could reconstitute the erythroid lineage, EGFP-
expressing populations were harvested and transplanted into
mutant embryos lacking erythroid cells (Fig. 3). Specifi-
cally, we wanted to see if cells from the ICM during theular systems in wild-type and mutant embryos. (A) In LR embryos, DsRed
ietic (white arrowheads) and endothelial cells (DofC: ducts of Cuvier). (B)
basilar artery; Ant, Anterior; Post, posterior; Do, dorsal; Vent, ventral). (C)
bryo displaying green/red cranial vessels (arrow, V) and red erythrocytes
(arrowhead) and endothelial cells (arrows) in 24 hpf and 3 dpf embryos. In
rculate through vessels (arrows) labeled by DsRed as shown in 24 hpf and
embryos carry the Tg(lmo2:EGFP) transgene. (H) In the zebrafish cloche
; EGFP expression is restricted to the posterior ICM (arrow), where lmo2
present (arrow), but erythrocytes are absent. (J) In mindbomb, vascular
hen EGFP-labeled cells travel from aorta into vein.
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ropoiesis, (2) differentiate into endothelial cells, and (3)
exhibit HSC activity. To track donor-derived erythrocytes
over a long time period, we used Tg(gata1:DsRed), a
transgenic line expressing DsRed under the control of the
gata1 promoter (Long et al., 1997; Traver et al., 2003).
EGFP+ donor cells were FACS sorted to over 90% purity
from 10- to 12-somite stage LGb; Tg(gata1:DsRed) double
transgenic embryos and injected into the circulation of 48
hpf vlt embryos (Fig. 3A). vlt mutants have an absolute
block in erythroid development due to a defect in the gata1
gene, which always results in lethality by 14 dpf (Lyons et
al., 2002; Traver et al., 2003).
Approximately equal numbers of circulating DsRed+ and
EGFP+ cells could be seen in the recipients 1 day after trans-
plantation (see Fig. 3B). By 3 days post transplantation, few
EGFP+ circulating cells were present and virtually all the cells
were DsRed+, suggesting that the EGFP+ progenitors hadig. 3. Transplantation of primitive progenitors into vlad tepes (vlt) recipients. (A)TheEGFP+population from10- to 12-somiteLGb;Tg(gata1:DsRed) transgenic
mbryos was isolated by FACS to 90% purity and transplanted into 48 hpf vlt embryos. (B) One day after transplantation, circulating donor-derived cells were
entified byDsRed and EGFP fluorescence. By 3 days post transplantation, most circulating cells wereDsRed+, suggesting that the EGFP+ donor progenitors had
ifferentiated into Gata1+ erythrocytes (arrow). One month after transplantation, each of the 8 survivors carried approximately 10–200 DsRed+ circulating cells




(adifferentiated into Gata1 expressing erythrocytes (Fig. 3B).
After 1 week, we detected no increase in the number of cir-
culating cells. In addition, no EGFP+ endothelial structures
were identified up to this point, suggesting that the donor cells
did not contribute to angiogenesis at this time. One month
after transplantation, 8 of 30 transplanted individuals were
alive, whereas no surviving untransplanted mutant embryos
had survived (Fig. 3C). Each of these survivors contained
between 10 and 200 cells in circulation, virtually all of which
were DsRed+ and therefore donor derived. This was a
smaller number of cells than had been initially transplanted,
demonstrating that a robust expansion of the erythroid
lineage had not occurred. At 2 months, the 8 fish were still
alive, but no circulating blood cells were observed. FACS
analysis of recipients’ kidney marrow also revealed a total
absence of erythroid populations (data not shown). We
cannot rule out the possibility that the donor cells contributed
to lymphocyte and myleomonocyte compartments—to do
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specific transgene, which does not currently exist.
At the 1-month time point, we also observed EGFP+
endothelial cells of the trunk vasculature in 2 of the 8
surviving recipients (Fig. 3B; see also SupplementalMovies 2
in Appendix A). We expected to see donor-derived
endothelial cells, but not EGFP expression at this later time
point. Because cells were transplanted directly into circu-
lation, we speculate that it was difficult for angioblasts to
integrate into the nascent vascular network. The cells that
did integrate may have required 1 month to generate enough
tissue to be detected by fluorescence. Alternatively, there
may have been an earlier, robust integration of donor
angioblasts, but an immediate downregulation of EGFP
expression. Only later does EGFP expression become
reactivated, possibly as an angiogenic response to injury.
No EGFP+ vascular structures were found at the 2-month
time point. Our studies demonstrate that the transplanted
EGFP+ cells have blood and endothelial potential.
Identification of cis-regulatory elements in the lmo2
promoter
To map essential regulatory elements contained within the
2.5-kb lmo2 promoter [LG2.5 = Tg(lmo2:EGFP)-promoter
length], a deletion series of promoter constructs was
generated and injected into one-cell embryos. EGFP expres-
sion was assayed at 24 and 30 hpf to determine transgene
expression levels and tissue specificity. Due to the mosaic
nature of transiently expressed transgenes, strong expression
of a construct was defined by an embryo that expressed more
than 20 cells in the ICM at 24 hpf. Blood and vascularFig. 4. Deletion analysis identifies a compact promoter that drives hematopoietic a
as N20 fluorescent cells in the ICM at 24–30 hpf) and relative levels of blood or va
the LG174 transgenic is shown at 5 somites, 18, 24, and 36 hpf. LG174 drives
arrows point to cv, cranial vessels; av, axial vessels), hematopoietic cells (white aexpression were discriminated at 30 hpf, when blood cells
circulate and endothelial cells outline vascular structures.
45% of embryos injected with LG2.5 showed strong
expression and robust blood and endothelial expression
(Fig. 4A). LG1.5, LG1.0, LG635, LG500, and LG174
produced 16%, 14%, 30%, 16%, and 22% strongly expressing
embryos, respectively, and exhibited similar expression
patterns to that of LG2.5. Further truncation of the promoter
down to LG69 completely abrogated activity, showing that
LG174 is the minimally active promoter, and suggesting that
the 103-bp region between174 and69 contains the critical
elements for lmo2 expression in appropriate tissues.
Two stable transgenic lines were then generated using the
LG174 promoter construct, one of which is shown in Fig. 4B.
Embryos from these lines show that LG174 contains the
elements sufficient to direct expression to the mesodermal
stripes, circulating blood cells, and vascular structures (Fig.
4B). Preservation of the essential aspects of lmo2 expression
from early somitogenesis to 36 hpf indicates that the key
elements of lmo2 transcription are contained within LG174.
In order to identify evolutionarily conserved regulatory
elements, we compared the 2.5-kb zebrafish lmo2 sequence to
mouse, human, chicken and pufferfish (Fugu rubripes).
Neither fish species showed homology to chicken or mam-
mals, but a 53-bp sequence between 174 and 69 is 82%
conserved between zebrafish and Fugu (sequence shown in
Fig. 5A). Within this region, three conserved ETS-domain
transcription factor core binding sequences (GGAA) were
identified and designated EBS1, EBS2, and EBS3. Since
many EBSs are critical for hematopoietic and vascular pro-
moters, we hypothesized that ETS factors might regulate
lmo2. To test this, mutations in each EBS were generated.nd vascular expression. (A) The percentages of bstrong expressersQ (defined
scular expression at 30 hpf are shown. (C) The developmental expression of
expression in the mesodermal stripe (ms, arrowhead), vascular cells (black
rrow, ICM), and trunk somites (black arrowhead, ts).
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reduction of total EGFP expression, whereas mutations in
EBS1 or EBS3 did not significantly alter expression (Fig. 5B).
In the context of the entire 2.5-kb promoter, the EBS2
mutation alone did not alter hematopoietic or endothelial
expression. To test if the three EBS were functioning
redundantly, wemutated all three sites. This mutant promoter,
LG2.5e1,2,3-, exhibited significantly reduced vascular but
normal blood expression, demonstrating that ETS motifs
play a role in the endothelial activity of the 2.5-kb promoter.
To address the requirement of the 103-bp region between
174 and 69 in the context of the 2.5-kb promoter, we
deleted 174/69 from the promoter to produce construct
LG2.5D170/67. In transient injection assays, this pro-
moter maintained strong activity in hematopoietic cells (23%Fig. 5. Dissection of the lmo2 regulatory elements. (A)A 51-bp region fromwithin th
lmo2 locus. The three conserved ETS-factor binding sites (EBS) in this region are bo
strong expression is significantly decreased in ICMcells.WhenEBS1, EBS2, andEB
normal, but endothelial expression is significantly reduced.When the region between
expression is not seen, but blood expression is preserved.Removal of174/+41 (LG2
of LG2.5D170/67 at 24 and 36 hpf. At 24 hpf, the ICM is filled with EGFP+ ce
(arrowhead) moving towards the heart at 36 hpf. No expression is seen in vascularof embryos) (Fig. 5B), but failed to activate expression in any
endothelial cells (Figs. 5B,C), demonstrating that critical
endothelial elements are contained within the 103-bp region
between 174 and 69 and suggesting that transcription in
blood and vascular cell types can be uncoupled (Fig. 5D).
LG69 is incapable of any expression, so the ability to drive
hematopoietic expression after adding the 5V fragment
2500/174 indicated the presence of either a 2nd hema-
topoietic promoter or an enhancer between2500 and174.
We ruled out the possibility of a second promoter by showing
that the2500/174 fragment alone was unable to drive any
expression (see construct LG2.5D170/+41 in Fig. 5B). In
support of this result, 5V RACE using lmo2 specific primers
identified the previously cloned 5V UTR downstream of
LG69, but did not reveal alternative transcripts that woulde LG174 zebrafish promoter is 82% conservedwith a 53-bp region in the fugu
xed. (B) Red triangles label EBSmutations.WhenEBS2 ismutated in LG174,
S3 aremutated in the context of the entire 2.5-kbpromoter, blood expression is
174 and69 is removed from LG2.5 (called LG2.5D170/67), vascular
.5D170/+41) resulted in no expression. (C)The transient expression pattern
lls (arrowhead) that are in circulation by 36 hpf. The inset shows blood cells
endothelium at either stage. D shows the organization of lmo2 cis-elements.
Fig. 6. lmo2 is coexpressed with multiple ETS factors. (A) Developmental
expression of ets1 and lmo2 at the 5-somite, 24 and 36 hpf stages. Both genes
are expressed in the posterior mesoderm at 5 somites (arrowheads). At 24 hpf,
both are expressed in the ICM, cranial (cv), and axial vessels (av). At 36 hpf,
lmo2 is maintained in endothelial and circulating cells (arrowhead) while
ets1 is in a subset of vessels but is not seen in circulating blood. (B) Other
ETS factors are coexpressed with lmo2 in the ventral mesoderm at the 5-
somite stage and ICM at 24 hpf. fli1a, fli1b, andmef/elf4 are ETS factors that
could have redundant or cooperative roles with ets1 in regulating lmo2.
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produces robust blood expression while LG2.5D170/+41
cannot generate any expression, it follows that LG69 contains
a basal promoter on which the hematopoietic enhancer ele-
ment(s) is dependent. LG69 contains an Sp1 site and a TATA
box, motifs common to basal promoters. These data show that
zebrafish lmo2 locus contains hematopoietic and vascular
enhancers that operate on a single promoter, in contrast to the
human lmo2 locus, which contains two known promoters that
drive expression indistinct tissues (Royer-Pokoraet al., 1995).
Analysis of the zebrafish lmo2 promoter revealed that (1) a
compact 174-bp promoter sufficient to drive the lmo2
expression pattern is dependent on an EBS, (2) a 103-bp
region containing three highly conserved EBSs within the
174-bp promoter is necessary for vascular but not blood
expression, and (3) a distal hematopoietic enhancer operates
through a proximal basal promoter within the 174-bp element
(summarized in Fig. 5D).
ETS factors are coexpressed with lmo2 and participate in
promoter activity
In an effort to identify candidate factors that might regulate
the promoter, we analyzed the expression of seven ETS
factors that had been previously cloned in zebrafish and found
that ets1, fli1a, fli1b, and mef were coexpressed with lmo2
during early development (see Fig. 6A). Zebrafish Ets1, the
founding member of the ETS-domain transcription factor
family, is 83% conserved with human ETS-1. Expression of
ets1 and lmo2 appeared to overlap in the posterior lateral
mesoderm at the 5-somite stage, although the ets1 domain
was wider and extended further caudally around the tail bud
(Fig. 6A, row 1). At 24 hpf, ets1 was expressed in the ICM as
well as the cranial, axial, and intersomitic vessels (Fig. 6A,
row 2). Notably, ets1 was not in the ducts of Cuvier, where
pooled blood is seen at 36 hpf (Fig. 6A, row 3). By 48 hpf,
transcripts of both genes disappeared from trunk tissues. This
positions ets1 as a candidate for the early patterning of lmo2 as
well as a later regulator of lmo2 in vascular cell types.
We also identified several other factors that are coex-
pressed with lmo2 (Fig. 6B). Here, we refer to fli1 as fli1a in
order to introduce fli1b, a closely related ETS factor identifiedFig. 7. ets1 and mef bind to the lmo2 promoter; ets1 activates the lmo2 promoter th
binding to oligo wtEBS1. Lane 1 contains labeled probe without lysate. Several no
lysate (lane 2). Neither version of ets1 can bind to labeled wtEBS1 (lanes 3 and 4)
probes (e2-, e3-). Lane 1 contains labeled probe without lysate. A nonspecific band
Wild-type ets1 exhibits minimal binding (lane 3), while ets1DN binds robustly (lane
500 excess of unlabeled wtEBS2,3 (lanes 5 and 6) as well as unlabeledmutant com
compete away binding, which demonstrates that ets1DN specifically binds to EBS2
The third EMSA shows mef binding to oligo wtEBS2,3 (lane 3). Lanes 4 and 5 sho
EBS3 can be competed off. (B) Shown in the first row of this panel are LGb embryos.
mesoderm, and tailbud expression. In the second row, increased ICM as well as diffu
row, ets1 overexpression expands the lmo2 domain into the paraxial mesoderm. (C) S
ets1-injected embryos have higher levels of EGFP expression globally and locally i
injected with wild-type reporter construct LG174, but only has minimal activity w
through the binding of EBS2 in vivo. (D) Morpholino knockdown of ets1 (ets1 splic
severe reduction in ets1 as measured by whole mount in situ hybridization, demonin our laboratory. The expression patterns of fli1a and lmo2
are almost identical during early development (Brown et al.,
2000). fli1b was first detected at 5 somites in the posterior
mesoderm and was restricted to vascular tissues throughout
embryogenesis, making it a potential regulator of lmo2 ex-
pression in endothelial cells. mef is expressed in lymphoid,rough EBS2. (A) EMSA of wild-type ets1 and C-terminal truncated ets1DN
nspecific bands appear when labeled probe is incubated with unprogrammed
. The second EMSAwas performed with wild-type (wtEBS2,3) and mutant
appears when labeled probe is incubated with unprogrammed lysate (lane 2).
4). ets1DN is used in lanes 4–10. Competition was performed with 50 and
petitors (lanes 7–10). Lanes 7 and 8 show that the e2- mutant oligo is unable to
. Alternatively, lanes 9 and 10 show that there is no specific binding to EBS3.
w that mef specifically binds to EBS2 and lanes 6 and 7 show that binding to
ets1-injected LGb embryos exhibit a widened EGFP domain, diffuse paraxial
se expression of EGFP are seen in injected LGb embryos at 22 hpf. In the third
hown in the first row are LG174 stable transgenic embryos; within this group,
n the stripes. ets1 activates EGFP expression in the yolk syncytium when co-
hen co-injected with LG174e2-, suggesting that ets1 activates the promoter
e-MO) does not affect transgene expression. These morphant embryos have a
strating morpholino efficacy.
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role in NK cell formation in the mouse (Lacorazza et al.,
2002). In zebrafish,mef was expressed globally from 5 somi-
tes to 30 hpf and focally in trunk vessels and pronephric ducts.Electrophoretic Mobility Shift Assay was performed to
demonstrate direct interaction between these ETS factors and
the three conserved EBSs. Only ets1 andmef were capable of
binding any of the EBSs of interest (see Fig. 7A; data for fli1a
H. Zhu et al. / Developmental Biology 281 (2005) 256–269266and fli1b not shown). Since it is known that ets1 contains
several autoinhibitory domains that can prevent direct in vitro
binding to consensus ETS-binding sites (Hagman and
Grosschedl, 1992), we truncated 19aa from the C-terminus
of ets1 to remove a known autoinhibitory domain. The
resulting protein, ets1DN, showed robust binding to an oligo
containing EBS2 and EBS3 (wtEBS2,3), but not to an oligo
containing EBS1 (wtEBS1). Binding to labeled wtEBS2,3
could be out-competed with unlabeled wtEBS2,3 and e3-, an
oligo with an EBS3 mutation. Binding could not be out-
competed with e2-, which contains an EBS2 mutation. These
results demonstrate that a truncated version of ets1 can
specifically bind EBS2 but not EBS1 or EBS3. These
findings also suggest that posttranslational modification or
interactions with other factors might repress ets1 auto-
inhibition during transcriptional activity in vivo. Similarly,
wild-type mef was able to bind specifically to EBS2 but not
EBS3 (Fig. 7A).
Since ets1 and mef were coexpressed with lmo2 and
could bind elements in its promoter, we overexpressed these
factors in the transgenic lines. mef mRNA overexpression
had no effect on transgene expression (data not shown). In
contrast, ets1 overexpression in LGb embryos induced
ectopic activity of the lmo2 promoter. At 5 somites, injected
embryos exhibited broader EGFP stripes, which were
expanded medio-laterally toward the midline. Diffuse
expression of EGFP was present in the paraxial mesoderm
and tailbud (Fig. 7B, row 1). At 22 hpf, EGFP protein was
produced ubiquitously and the ICM exhibited higher levels
of fluorescence (Fig. 7B, row 2). Injected embryos also
showed an expansion of endogenous lmo2 (Fig. 7B, row 3).
As a control, we also injected fli1a, which did not bind the
promoter element, but was able to cause ectopic transgene
expression (data not shown). This suggests that fli1a either
indirectly activates the lmo2 promoter through the activity
of other factor(s), or that fli1a, as a partner in a complex,
exerts its activity without direct DNA contact. Our data
support a model in which ETS factors, either directly or
indirectly, have activity on the lmo2 promoter.
We then sought to determine if ets1 actually exerted its
activities through EBS2 in vivo. First, ets1 overexpression
could expand transgene expression in LG174 embryos (Fig.
7C, row 1). To localize ets1-sensitive elements, we co-
injected ets1 mRNA with promoter constructs and assayed
for fluorescent activity. EGFP levels increased dramatically
when LG174 DNA and ets1 mRNA were co-injected as
compared to when the DNA construct was injected alone
(see Fig. 7C, row 2). In contrast, little to no activity was
produced when ets1 was co-injected with LG174 containing
a mutated EBS2 site (LG174e2-) (see Fig. 7C, row 3),
suggesting that ets1 acts specifically through EBS2 in vivo.
To test if ets1 is necessary for lmo2 expression, we used
a splice junction morpholino (ets1-spliceMO) to disrupt ets1
translation. The hematopoietic and vascular tissues in these
embryos developed normally, and EGFP transgene expres-
sion was unaffected (Fig. 7D). In situ hybridization showedseverely decreased ets1 transcript levels, confirming mor-
pholino efficacy. These data are consistent with mouse loss-
of-function experiments, which have shown that Ets-1 is
necessary for NK cell development and normal lymphocyte
function, but not HSC formation or de novo vessel
formation (Barton et al., 1998; Bories et al., 1995;
Muthusamy et al., 1995). Our data suggest that it is unlikely
that ets1 acts alone to regulate lmo2 expression, vasculo-
genesis, or HSC development, but that several ETS factors
participate in the regulation of lmo2 in zebrafish.Discussion
In this report, we have used a combination of trans-
plantation experiments and promoter analysis to demon-
strate that 2.5 kb of sequence proximal to the lmo2 gene can
drive robust expression in developing blood and vascular
cells. Overall, these transgenic lines will continue to serve as
useful reagents for experiments in vascular and hemato-
poietic development in zebrafish.
The lmo2 transgenic line is a tool for transplantation assays
The origin of the first HSCs during embryogenesis
remains controversial. The AGM is a source of definitive
HSCs when transplanted into lethally irradiated adult
animals, whereas yolk sac progenitors from b11.0 dpc
donors do not produce long-term engraftment of adults
(Medvinsky and Dzierzak, 1996; Medvinsky et al., 1996;
Muller et al., 1994). Yolk sac cells from 9.0 dpc are capable
of long-term engraftment when transplanted into condi-
tioned newborn mice (Yoder et al., 1997). Furthermore, yolk
sac cells cultured on AGM-derived stromal cells acquire the
ability to reconstitute hematopoiesis in lethally irradiated
adults (Matsuoka et al., 2001). This has led to the notion that
the yolk sac can give rise to HSCs, but that these cells need
to be exposed to signals in the appropriate microenviron-
ment before being able to repopulate adults. The lmo2
transgenic line enabled us to test the activity of primitive
wave populations in zebrafish hematopoietic transplantation
assays. Using this reagent, we showed that the first
identifiable blood-committed progenitors in zebrafish differ-
entiated into Gata1+ erythrocytes and extended the life span
of gata1/ mutant embryos, but did not demonstrate long-
term reconstitution of the erythroid lineage.
We have previously observed that similar erythropoietic
mutants such as Frescati can survive, albeit rarely, with a
complete absence of erythrocytes. The survivors remain
small in size, however, and we hypothesize that they can
minimally oxygenate their tissues by diffusion. We therefore
conclude that vlt recipients rescued from their normal
embryonic death by transplantation resulted from the
transient repopulation of erythrocytes by lmo2+ precursors.
Our group has previously shown that whole kidney marrow
from adult zebrafish can produce long-term (N6 months)
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2003). The ability of adult marrow cells to demonstrate
long-term hematopoietic reconstitution, but failure of
embryonic Lmo2+ to do the same, suggests that embryonic
Lmo2+ precursors can differentiate into erythrocytes for
approximately 1 month, but do not possess long-term stem
cell activity. We cannot rule out the possibility that the
transplanted cells were too mature at the time of harvest, or
that the host embryo was not at the appropriate stage to
provide the proper microenvironment. This experiment lays
the groundwork for future work, which will exploit these
methods and tools to home in on the stage and anatomical
location of the first HSCs in zebrafish.
Lmo2+ precursors were also able to contribute to adult
vascular structures in a subset of recipients. It is possible
that cells with bipotent potential were transplanted, but it is
more likely that two distinct populations of progenitors
consisting of early erythropoietic and endothelial cells were
transplanted. To distinguish between these hypotheses,
further experiments to elucidate the differentiation potential
of the early lmo2 precursors will be required.
The lmo2 promoter is an bintegrated circuitQ for
hematopoietic and vascular specification
In order to identify critical cis-regulatory elements and
upstream regulators of Lmo2 expression, we performed an
extensive mapping of the 2.5-kb promoter. This analysis
revealed several key observations: (1) the minimally active
174-bp proximal promoter is sufficient to drive hemato-
poietic and vascular expression, (2) the 2.5-kb promoter
contains separable hematopoietic and vascular cis-
elements, and (3) the zebrafish lmo2 locus contains a
single promoter through which these enhancer elements
operate (see Fig. 5D).
The small 174-bp fragment can recapitulate the spatial
and temporal aspects of a complex two-tissue expression
pattern. We believe that this region of the promoter is of
critical importance, since it alone can generate the lmo2
expression pattern precisely when the earliest blood and
vascular marker genes appear in the mesoderm. We infer
that the inductive signals that specify hematopoietic and
vascular tissues operate on this part of the promoter. 51 bp
of this promoter were highly conserved with pufferfish lmo2
sequences, suggesting that these sequences are crucial
determinants of the lmo2 expression pattern in teleost fish.
In support of this observation, we demonstrated that this
element contains a critical ETS motif, without which the
proximal promoter does not function.
Several promoters and enhancers of both murine and
human Scl/Tal-1 expression have been identified (Aplan et
al., 1990; Begley, 1994; Bernard et al., 1990; Bockamp et al.,
1995, 1997, 1998). Only one of these, an enhancer located
within the 3V region of the murine Scl/Tal-1 locus, has been
shown to simultaneously direct expression to HSCs, blood
and vascular cells during embryonic and adult development(Sanchez et al., 1999, 2001). Mapping of this enhancer
defined a functional 641-bp element that contains critical
GATA and ETS motifs (Gottgens et al., 2002). The proximal
174-bp lmo2 promoter is similar to this Scl/Tal-1 enhancer in
that both are compact elements dependent on ETS motifs that
can direct blood and vascular expression (Gottgens et al.,
2002, 2004). This suggests that the expression of Scl/Tal-1
and lmo2 are controlled by common upstream ETS factors,
perhaps accounting for the extensive overlap in expression
domains of these genes during development.
While much data have made ETS factors attractive
candidates for patterning within the mesoderm, no single
ETS factor has been shown to be indispensable for early
hematopoietic or vascular development (Bassuk and Leiden,
1997; Crepieux et al., 1994; Donaldson et al., 1996).
Likewise, ets1 is coexpressed with lmo2, its overexpression
is sufficient to produce ectopic lmo2 expression, but it is not
required for zebrafish lmo2 expression. It is possible that
multiple ETS factors are redundantly involved in Scl/Tal-1
and lmo2 transcription. We hypothesize that ets1 may
cooperate with other ETS factors that may be required in
tandem for lmo2 regulation. Consistent with this idea, we
have found that ets1, fli1a, fli1b, and mef/elf4 are coex-
pressed with lmo2 in endothelial and/or hematopoietic cells.
Given the ability of ets1 and fli1a to activate the lmo2
promoter, it is likely that several other ETS factors could be
sufficient for transcriptional activation of lmo2. We attemp-
ted triple morpholino knockdown experiments with ets1/
fli1a/fli1b as well as ets1/fli1a/mef, but neither of these
combinations could alter lmo2 expression or affect vessel
development (data not shown). Using more genes or higher
doses in the morpholino cocktail was prohibited by
excessive toxicity. Further studies will be required to find
a combination that is necessary for lmo2 expression.
Our results also demonstrate the existence of a distal
hematopoietic enhancer element. This element would be
partially redundant with the hematopoietic component of the
174-bp proximal promoter. When the previously mentioned
core 641-bp SCL enhancer was abrogated using a knockout
approach, hematopoiesis and Scl/Tal-1 transcription were
not affected (Gottgens et al., 2004). Subsequently, another
enhancer containing functional ETS motifs that directed
expression to the endothelium and hematopoietic progeni-
tors was identified, demonstrating partial redundancy of
these elements. The existence of redundant enhancers
controlling both lmo2 expression in zebrafish and Scl/Tal-
1 in mouse suggests the parallel evolution of an important
regulatory strategy for early hematopoietic and vascular
gene transcription.
Further study of these and other aspects of lmo2 regulation
will provide insights into HSC formation and homeostasis. A
better knowledge of the regulatory circuitry underlying HSC
biology will be critical for understanding the pathophysiol-
ogy of malignancies such as T-ALL, and for stem-cell-based
therapies that are aimed at coaxing embryonic stem cells to
differentiate into HSCs in vitro. In addition, several gene
H. Zhu et al. / Developmental Biology 281 (2005) 256–269268therapy patients demonstrated retroviral vector integrations
into the Lmo2 gene, suggesting that in HSCs, the Lmo2
gene could be open at a chromatin level. The study of
Lmo2 gene regulation will have clinical ramifications for
gene therapy and hematopoietic malignancies.Acknowledgments
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